open access
Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies
, 1, 2, 2, 1, 3, 1, 2, 2, 1, 1
Affiliations- Department of Neurology, Medical University of Bialystok, Bialystok, Poland
- Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland
- Independent statistic consultant
open access
Abstract
Clinical rationale for the study. The course of COVID-19 in people with multiple sclerosis (PwMS) has been described, while the serological status after SARS-CoV-2 infection or vaccination, especially in patients treated with disease-modifying therapies (DMT), is still under investigation. This is a significant clinical problem, as certain DMTs may predispose to a severe course of viral infections.
Aim of the study. We analyzed the presence of antibodies against spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 in relapsing-remitting PwMS treated with DMT, especially dimethyl fumarate, interferon beta, and glatiramer acetate, in a single multiple sclerosis (MS) centre in north-eastern Poland (the Department of Neurology, Medical University of Bialystok).
Material and methods. The presence of antibodies against S and N proteins in PwMS was assessed twice: on visit one (between May and June 2020) (n = 186) and on visit two (between May and June 2021) (n = 88). Samples were taken from 68 individuals on both visits. Demographic and clinical data was collected: duration of MS, Expanded Disability Status Scale Score (EDSS), type of DMT, history of COVID-19 (positive PCR or antigen test in the past), vaccination status, and the type of vaccine.
Results. It was shown that on visit one: 3.7% (n = 7) PwMS were positive for IgA against S protein (IgA-S), 3.2% (n = 6) for IgG against S (IgG-S) protein, and none of those examined was positive for IgG against N protein (IgG-N). On visit two, the most common detected antibodies were IgG-S (71.3%; n = 62), then IgA-S (65.1%; n = 55), and the least common was IgG-N (18.2%; n = 16). On visit two: 20.45% of PwMS had a history of a positive SARS-CoV-2 PCR or antigen test during the last year. By the time of visit two, 42.05% (n = 37) of patients who participated in visit two had been full-course vaccinated against COVID-19. It was demonstrated that vaccination against SARS-CoV-2 significantly induces the production of IgG-S and IgA-S (p < 0.0001), while no difference between vaccinated and unvaccinated patients was shown in the detection of IgG-N. There was no correlation between COVID-19 infection and antibodies against proteins S and N in the study group. Moreover, the presented study did not show any relationship between the ability to produce antibodies against the S protein with any of the used DMTs.
Conclusions and clinical implications. According to our study, PwMS treated with dimethyl fumarate, interferon beta, or glatiramer acetate can efficiently produce antibodies against SARS-CoV-2 both after infection and after vaccination.
Abstract
Clinical rationale for the study. The course of COVID-19 in people with multiple sclerosis (PwMS) has been described, while the serological status after SARS-CoV-2 infection or vaccination, especially in patients treated with disease-modifying therapies (DMT), is still under investigation. This is a significant clinical problem, as certain DMTs may predispose to a severe course of viral infections.
Aim of the study. We analyzed the presence of antibodies against spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 in relapsing-remitting PwMS treated with DMT, especially dimethyl fumarate, interferon beta, and glatiramer acetate, in a single multiple sclerosis (MS) centre in north-eastern Poland (the Department of Neurology, Medical University of Bialystok).
Material and methods. The presence of antibodies against S and N proteins in PwMS was assessed twice: on visit one (between May and June 2020) (n = 186) and on visit two (between May and June 2021) (n = 88). Samples were taken from 68 individuals on both visits. Demographic and clinical data was collected: duration of MS, Expanded Disability Status Scale Score (EDSS), type of DMT, history of COVID-19 (positive PCR or antigen test in the past), vaccination status, and the type of vaccine.
Results. It was shown that on visit one: 3.7% (n = 7) PwMS were positive for IgA against S protein (IgA-S), 3.2% (n = 6) for IgG against S (IgG-S) protein, and none of those examined was positive for IgG against N protein (IgG-N). On visit two, the most common detected antibodies were IgG-S (71.3%; n = 62), then IgA-S (65.1%; n = 55), and the least common was IgG-N (18.2%; n = 16). On visit two: 20.45% of PwMS had a history of a positive SARS-CoV-2 PCR or antigen test during the last year. By the time of visit two, 42.05% (n = 37) of patients who participated in visit two had been full-course vaccinated against COVID-19. It was demonstrated that vaccination against SARS-CoV-2 significantly induces the production of IgG-S and IgA-S (p < 0.0001), while no difference between vaccinated and unvaccinated patients was shown in the detection of IgG-N. There was no correlation between COVID-19 infection and antibodies against proteins S and N in the study group. Moreover, the presented study did not show any relationship between the ability to produce antibodies against the S protein with any of the used DMTs.
Conclusions and clinical implications. According to our study, PwMS treated with dimethyl fumarate, interferon beta, or glatiramer acetate can efficiently produce antibodies against SARS-CoV-2 both after infection and after vaccination.
Keywords
COVID-19, SARS-CoV-2, multiple sclerosis, disease-modifying therapies, antibodies, vaccines, serology
About this articleTitle
Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Research Paper
Pages
121-130
Published online
2022-11-24
Page views
2931
Article views/downloads
623
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2023;57(1):121-130.
Keywords
COVID-19
SARS-CoV-2
multiple sclerosis
disease-modifying therapies
antibodies
vaccines
serology
Authors
Joanna Kulikowska
Agata Czarnowska
Monika Gudowska-Sawczuk
Agnieszka Kulczyńska-Przybik
Marcin Bazylewicz
Francois Collins
Monika Chorąży
Barbara Mroczko
Jan Kochanowicz
Katarzyna Kapica-Topczewska
Alina Kułakowska
References (31)- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.
- Diagnosis and treatment plan of Corona Virus Disease 2019 (tentative sixth edition). Glob Health J. 2020; 4(1): 1–5.
- Kirtipal N, Bharadwaj S, Kang SGu. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect Genet Evol. 2020; 85: 104502.
- Wei J, Pouwels KB, Stoesser N, et al. COVID-19 Infection Survey team, COVID-19 Infection Survey team. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat Commun. 2021; 12(1): 6250–1082.
- McAndrews KM, Dowlatshahi DP, Dai J, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020; 5(18).
- Kulikowska J, Kulczyńska-Przybik A, Mroczko B, et al. The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis-A Literature Review. Int J Mol Sci. 2021; 22(11).
- Nicol T, Lefeuvre C, Serri O, et al. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). J Clin Virol. 2020; 129: 104511.
- Jalkanen P, Pasternack A, Maljanen S, et al. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics. J Infect Dis. 2021; 224(2): 218–228.
- Willis MD, Robertson NP. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. J Neurol. 2020; 267(5): 1567–1569.
- Lemus HN, Warrington AE, Rodriguez M. Multiple Sclerosis: Mechanisms of Disease and Strategies for Myelin and Axonal Repair. Neurol Clin. 2018; 36(1): 1–11.
- Kapica-Topczewska K, Collin F, Tarasiuk J, et al. Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland. Neurol Neurochir Pol. 2020; 54(2): 161–168.
- Kapica-Topczewska K, Tarasiuk J, Chorąży M, et al. The epidemiology of comorbidities among multiple sclerosis patients in northeastern Poland. Mult Scler Relat Disord. 2020; 41: 102051.
- Czarnowska A, Brola W, Zajkowska O, et al. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience. Neurol Neurochir Pol. 2021; 55(2): 212–222.
- Czarnowska A, Kapica-Topczewska K, Zajkowska O, et al. Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland. J Clin Med. 2021; 10(22).
- Burkill S, Montgomery S, Hajiebrahimi M, et al. Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012. Neurology. 2017; 89(6): 555–562.
- Capasso N, Palladino R, Montella E, et al. Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. J Clin Med. 2020; 9(12).
- Łoś K, Kulikowska J, Waszkiewicz N. The Impact of the COVID-19 Virus Pandemic on the Incidence of First Psychotic Spectrum Disorders. Int J Environ Res Public Health. 2022; 19(7).
- Łoś K, Kulikowska J, Waszkiewicz N. First-Time Psychotic Symptoms in a Patient After COVID-19 Infection-A Case Report. Front Psychiatry. 2021; 12: 726059.
- Flinck H, Rauhio A, Luukinen B, et al. Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19. Diagn Microbiol Infect Dis. 2021; 99(1): 115197.
- Covid- BS. OBSER-CO Raport z I tury badania. 2021.
- Piñar Morales R, Ramírez Rivas MA, Barrero Hernández FJ, et al. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis. Neurologia (Engl Ed). 2021 [Epub ahead of print]; 36(9): 698–703.
- van Kempen ZLE, Strijbis EMM, Al MM, et al. SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort. JAMA Neurol. 2021; 78(7): 880–882.
- Sormani MP, Schiavetti I, Landi D, et al. MuSC-19 Study Group. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Mult Scler. 2022; 28(7): 1034–1040.
- Sarjomaa M, Diep LMy, Zhang C, et al. SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway. PLoS One. 2022; 17(8): e0264667.
- Castro Dopico X, Ols S, Loré K, et al. Immunity to SARS-CoV-2 induced by infection or vaccination. J Intern Med. 2022; 291(1): 32–50.
- Drulovic J, Ivanovic J, Martinovic V, et al. Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies. Mult Scler Relat Disord. 2021; 54: 103150.
- Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020; 45: 102439.
- Chilimuri S, Mantri N, Gongati S, et al. COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab. Vaccines (Basel). 2021; 9(3).
- Tallantyre EC, Scurr MJ, Vickaryous N, et al. COVID-19 Vaccine Response in People with Multiple Sclerosis. Ann Neurol. 2022; 91(1): 89–100.
- Sormani MP, Inglese M, Schiavetti I, et al. CovaXiMS study group on behalf of the Italian Covid-19 Alliance in MS. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021; 72: 103581.
- Nishimura M, Sugawa S, Ota S, et al. Detection of silent infection of severe acute respiratory syndrome coronavirus 2 by serological tests. PLoS One. 2022; 17(5): e0267566.
